Eva Moritz
University of Zurich
10 Papers
Eva Moritz is an academic researcher from University of Zurich. The author has contributed to research in topics: Virus & Interferon. The author has an hindex of 6, co-authored 10 publications.
Chat about Author
Papers
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
Christoph Hock,Uwe Konietzko,Johannes Streffer,Jay Tracy,Andri Signorell,Britta Müller-Tillmanns,Ulrike Lemke,Katharina Henke,Eva Moritz,Esmeralda Garcia,M. Axel Wollmer,Daniel Umbricht,Dominique J.-F. de Quervain,Marc Hofmann,Alessia Maddalena,Andreas Papassotiropoulos,Roger M. Nitsch +16 more
TL;DR: It is established that antibodies against beta-amyloid plaques can slow cognitive decline in patients with Alzheimer's disease.
869
The Cellular RNA Helicase UAP56 Is Required for Prevention of Double-Stranded RNA Formation during Influenza A Virus Infection
TL;DR: It is demonstrated that UAP56 is utilized by influenza A viruses to prevent the formation of dsRNA and, hence, the activation of the innate immune response.
74
Interferon-induced antiviral protein MxA interacts with the cellular RNA helicases UAP56 and URH49.
TL;DR: It is proposed that Mx proteins exert their antiviral activity against IAV by interfering with the function of the RNA helicases UAP56 and URH49.
45
Active immunization of mice with an Abeta-Hsp70 vaccine.
Michael F. Koller,M. Hasan Mohajeri,Michael Huber,M. Axel Wollmer,Birgit Roth Z'graggen,Erika Sandmeier,Eva Moritz,Jay Tracy,Roger M. Nitsch,Philipp Christen +9 more
TL;DR: The production of an Hsp70-supported vaccine to induce the generation of antibodies against amyloid-β (Aβ) peptides, the major constituent of β-amyloid plaques in Alzheimer’s disease, emphasized the need for anti-Aβ antibodies that remove Aβ peptides from the central nervous system without negative side effects.
IFITM3 incorporation sensitizes influenza A virus to antibody-mediated neutralization.
Caroline Lanz,Michael Schotsaert,Carsten Magnus,Carsten Magnus,Carsten Magnus,Umut Karakus,Annika Hunziker,Milagros Sempere Borau,Carles Martínez-Romero,Eva E. Spieler,Sira C. Günther,Eva Moritz,Benjamin G. Hale,Alexandra Trkola,Adolfo García-Sastre,Silke Stertz +15 more
TL;DR: This article showed that IFITM3-mediated reduction in HA content sensitizes IAV to antibody-mediated neutralization, and showed that this effect decreases and delays peak IAV titers.